Sumitomo Mitsui Financial Group Inc. Has $2.29 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Sumitomo Mitsui Financial Group Inc. lessened its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 83.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 40,554 shares of the biopharmaceutical company's stock after selling 207,409 shares during the quarter. Sumitomo Mitsui Financial Group Inc.'s holdings in Bristol-Myers Squibb were worth $2,294,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. United Bank increased its stake in Bristol-Myers Squibb by 2.7% in the third quarter. United Bank now owns 17,322 shares of the biopharmaceutical company's stock valued at $896,000 after purchasing an additional 456 shares during the last quarter. Morse Asset Management Inc grew its stake in Bristol-Myers Squibb by 25.0% during the third quarter. Morse Asset Management Inc now owns 10,000 shares of the biopharmaceutical company's stock worth $517,000 after buying an additional 2,000 shares during the period. EP Wealth Advisors LLC increased its holdings in Bristol-Myers Squibb by 25.0% in the 3rd quarter. EP Wealth Advisors LLC now owns 49,252 shares of the biopharmaceutical company's stock valued at $2,548,000 after purchasing an additional 9,836 shares in the last quarter. iA Global Asset Management Inc. grew its stake in shares of Bristol-Myers Squibb by 81.3% in the third quarter. iA Global Asset Management Inc. now owns 76,775 shares of the biopharmaceutical company's stock valued at $3,972,000 after buying an additional 34,418 shares in the last quarter. Finally, Dunhill Financial LLC raised its stake in shares of Bristol-Myers Squibb by 39.8% during the third quarter. Dunhill Financial LLC now owns 664 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 189 shares during the period. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insider Activity at Bristol-Myers Squibb

In other news, EVP Samit Hirawat acquired 1,823 shares of Bristol-Myers Squibb stock in a transaction on Friday, February 14th. The stock was bought at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the transaction, the executive vice president now owns 63,932 shares of the company's stock, valued at $3,506,030.88. The trade was a 2.94 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 0.09% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Stock Up 0.4 %

Shares of BMY traded up $0.22 during mid-day trading on Friday, hitting $50.68. 13,408,290 shares of the company's stock were exchanged, compared to its average volume of 12,924,946. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The stock has a market cap of $103.11 billion, a price-to-earnings ratio of -11.46, a P/E/G ratio of 2.07 and a beta of 0.41. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The firm has a fifty day moving average of $57.71 and a two-hundred day moving average of $56.73.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. On average, sell-side analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be paid a $0.62 dividend. The ex-dividend date is Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 4.89%. Bristol-Myers Squibb's payout ratio is -56.11%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on BMY shares. Truist Financial increased their target price on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. The Goldman Sachs Group reissued a "neutral" rating and issued a $55.00 price target (down previously from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday. Wells Fargo & Company raised their target price on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research note on Friday, February 7th. Cantor Fitzgerald upped their price target on Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. Finally, UBS Group reduced their price objective on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, Bristol-Myers Squibb has an average rating of "Hold" and an average target price of $57.67.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.